CD274 and non-small cell lung carcinoma: The FDA has also approved three anti-PD-L1 antibodies—atezolizumab, durvalumab, and avelumab—for cancers such as urothelial carcinoma, non-small cell lung cancer (NSCLC), and Merkel cell carcinoma [97].